These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30364187)

  • 1. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4
    Chiodetti AL; Sánchez Vallecillo MF; Dolina JS; Crespo MI; Marin C; Schoenberger SP; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Morón G; Maletto BA
    Front Immunol; 2018; 9():2319. PubMed ID: 30364187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice.
    Moran MC; Bence AR; Vallecillo MFS; Lützelschwab CM; Rodriguez MG; Pardo R; Goldbaum FA; Zylberman V; Palma SD; Maletto BA; Estein SM
    Res Vet Sci; 2021 Mar; 135():217-227. PubMed ID: 33631456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice" [Toxicon 215 (2022) 28-36].
    Fusco LS; Pascual MM; Hernandez D; Sánchez Vallecillo MF; Arrieta MB; Moron G; Palma S; Maletto BA; Leiva LC
    Toxicon; 2022 Sep; 216():114. PubMed ID: 35841861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A liquid crystal of ascorbyl palmitate, used as vaccine platform, provides sustained release of antigen and has intrinsic pro-inflammatory and adjuvant activities which are dependent on MyD88 adaptor protein.
    Sánchez Vallecillo MF; Minguito de la Escalera MM; Aguirre MV; Ullio Gamboa GV; Palma SD; González-Cintado L; Chiodetti AL; Soldano G; Morón G; Allemandi DA; Ardavín C; Pistoresi-Palencia MC; Maletto BA
    J Control Release; 2015 Sep; 214():12-22. PubMed ID: 26188153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
    Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
    ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved biodistribution and enhanced immune response of subunit vaccine using a nanostructure formed by self-assembly of ascorbyl palmitate.
    Marin C; Ruiz Moreno FN; Sánchez Vallecillo MF; Pascual MM; Dho ND; Allemandi DA; Palma SD; Pistoresi-Palencia MC; Crespo MI; Gomez CG; Morón G; Maletto BA
    Nanomedicine; 2024 Jun; 58():102749. PubMed ID: 38719107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
    Liu Y; Luo X; Yang C; Yu S; Xu H
    Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.
    Hanagata N; Li X; Chen MH; Li J; Hattori S
    Int J Nanomedicine; 2018; 13():43-62. PubMed ID: 29317815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
    Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
    J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Vaccine Based on Kunitz-Type Molecule Confers Protection Against
    Silvane L; Celias DP; Romagnoli PA; Maletto BA; Sanchez Vallecillo MF; Chiapello LS; Palma SD; Allemandi DA; Sanabria REF; Pruzzo CI; Motrán CC; Cervi L
    Front Immunol; 2020; 11():2087. PubMed ID: 33193292
    [No Abstract]   [Full Text] [Related]  

  • 13. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
    Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
    J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
    Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
    Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes.
    Cheng WK; Wee K; Kollmann TR; Dutz JP
    Clin Vaccine Immunol; 2014 Mar; 21(3):329-39. PubMed ID: 24391136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
    Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
    J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
    Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
    J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.